Few data are available on specific treatments for hypertension in patients with either STEMI or non ST-segment elevation ACS, including both UA and NSTEMI. 5.1. Prevalence and Impact on Prognosis Contemporary data from the National Cardiovascular Data Registry (NCDR) Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry Get With The Guidelines (GWTG) demonstrate a prevalence of hyperten- sion of 65.2% among patients with STEMI and 79.2% among those with NSTEMI (ACTION Registry GWTG 2012 first- quarter report). The prevalence of hypertension increases notably with age among ACS patients, with hypertension prevalence rates approximately double among individuals >75 versus those <45 years of age.178 The impact of hypertension on outcomes in ACS is com- plex. In patients with stabilized ACS enrolled in the Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes (SYMPHONY) trials, hypertension was an independent predictor of death and Moreover, hypertension is integrated into the Thrombolysis in Myocardial Infarction risk score for UA/ NSTEMI as one of several classic risk factors for CAD, and the variable of 3 risk factors for CAD was independently associ- ated with the composite end point of mortality and recurrent However, other multivariable risk models have not found hypertension, defined as a yes/no categorical variable, to be independently associated with in-hospital mor- tality. Indeed, lower BP more typically emerges as predictive of poor outcomes in contemporary evaluations. In both the Global Registry of Acute Coronary Events (GRACE)180 and ACTION- registries, for example, in-hospital mortality Rosendorff et al Treatment of Hypertension in Patients With CAD 1389 increased by 20% for every 10-mmHg decrease in BP at presentation. 